Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.61 |
| ▸ | TNKS | O95271 | 1/20 | 0.61 |
| ▸ | WNT3A | P56704 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9178009 | 0.85 | KMT2A (1.00) | KMT2AMAOBTNKS2KDM4ESMN1; SMN2 | |
| SCHEMBL406051 | 0.82 | PDE5A (0.63) | KMT2AMAOBKDM4ESMN1; SMN2MAPT | |
| SCHEMBL31716910 | 0.82 | KMT2A (0.80) | KMT2AMAOBTNKS2TNKSKDM4E | |
| SCHEMBL28957724 | 0.82 | KMT2A (0.80) | KMT2ATNKS2TNKSKDM4ESMN1; SMN2 | |
| SCHEMBL7978349 | 0.78 | KMT2A (0.74) | KMT2ATNKS2KDM4ESMN1; SMN2PKM | |
| SCHEMBL20564672 | 0.78 | KMT2A (0.73) | KMT2AMAOBTNKS2TNKSKDM4E | |
| SCHEMBL31716237 | 0.77 | KMT2A (0.72) | KMT2ATNKS2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL28761526 | 0.77 | TNKS2 (0.64) | KMT2ATNKS2TNKSWNT3AKDM4E | |
| SCHEMBL11284110 | 0.76 | TNKS (1.00) | TNKS2TNKSWNT3AKDM4EMAPT | |
| SCHEMBL28206567 | 0.75 | TUBB4A (0.58) | KMT2AMAOBTNKS2TNKSWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | KMT2A 1424/4885MAOB 4179/4885TNKS2 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.